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Background: Epilepsy is the most common neurological disorder after stroke, affecting more than 50 million
persons worldwide. Metabolic disturbances are often associated with epileptic seizures, but the pathogenesis of this
relationship is poorly understood. It is known that seizures result in altered glucose metabolism, the reduction of
intracellular energy metabolites such as ATP, ADP and phosphocreatine and the accumulation of metabolic
intermediates, such as lactate and adenosine. In particular, it has been suggested that the duration and extent of
glucose dysregulation may be a predictor of the pathological outcome of status. However, little is known about
neither the effects of glycemic control on brain metabolism nor the effects of managing systemic glucose
concentrations in epilepsy.
Results: In this study, we examined glycemic modulation of kainate-induced seizure sensitivity and its
neuropathological consequences. To investigate the relationship between glycemic modulation, seizure
susceptibility and its neuropathological consequences, C57BL/6 mice (excitotoxin cell death resistant) were
subjected to hypoglycemia or hyperglycemia, followed by systemic administration of kainic acid to induce seizures.
Glycemic modulation resulted in minimal consequences with regard to seizure severity but increased hippocampal
pathology, irrespective of whether mice were hypoglycemic or hyperglycemic prior to kainate administration.
Moreover, we found that exogenous administration of glucose following kainic acid seizures significantly reduced
the extent of hippocampal pathology in FVB/N mice (excitotoxin cell death susceptible) following systemic
administration of kainic acid.
Conclusion: These findings demonstrate that modulation of the glycemic index can modify the outcome of brain
injury in the kainate model of seizure induction. Moreover, modulation of the glycemic index through glucose
rescue greatly diminishes the extent of seizure-induced cell death following kainate administration. Our data
support the hypothesis that deficient insulin signaling may represent a critical contributing factor in the
susceptibility to seizure-induced cell death and this may be an important therapeutic target.
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Mouse strainBackground
Epilepsy is the most prevalent chronic neurologic dis-
order affecting over 3 million Americans of all ages [1,2]
and is frequently refractory to current medical treat-
ments [3]. Temporal lobe epilepsy (TLE), the most com-
mon form of epilepsy, produces a state of chronic
neuronal hyperexcitability and hypersynchrony that is
manifested as recurrent unprovoked partial seizures [4].
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reproduction in any medium, provided the oris characterized by severe segmental neuronal loss in
CA1, CA3, and the hilar region and is accompanied by
pronounced astrogliosis [7]. Although the evidence
of brain damage in humans, as a result of convulsive
status epilepticus (SE), has been difficult to define or
quantify, the marked variability in susceptibility to
seizure-induced cell damage has been attributed to dif-
ferences in the underlying pathology, age, and seizure
type and duration [8-11]. Regardless, the molecular
mechanisms involved in the pathogenesis of hippocam-
pal sclerosis remain highly obscure. Thus, insight into
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post-seizure treatment exists to prevent this brain injury.
Many of the pathophysiological consequences of
human TLE (e.g. hippocampal sclerosis, mossy fiber
sprouting, spontaneous seizures) are faithfully repro-
duced in the kainic acid (KA) chemoconvulsant rodent
model of epilepsy [11-16]. Kainic acid, a potent agonist
of the α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic
acid/kainate class of glutamate receptors, is a powerful
excitant and excitotoxin, which when injected directly
into the brain or systemically induces a characterized
pattern of persistent seizure activity [17], activates iono-
tropic glutamate receptors, and selectively induces exci-
totoxic cell death in postsynaptic neurons in the CA3
and CA1 hippocampal subfields and within the dentate
hilus, while sparing neurons in the dentate granule cell
layer [18-21]. Thus, KA administration has been widely
used as a model to study excitotoxicity and seizure-
related neurologic diseases [17,22].
While administration of kainic acid to rodents results
in acute induction of seizures and subsequent neuronal
damage, inbred mouse strains significantly differ in
their pattern of hippocampal neurodegeneration in the
KA model of TLE [23-29]. Interestingly, the duration
or severity of seizure activity in response to KA is not
predictive of subsequent hippocampal cell death.
Although C57BL/6 (B6) and FVB/N (FVB) mouse strains
exhibit comparable seizure activity following systemic
administration of kainic acid (KA), C57BL/6 mice show
essentially no hippocampal cell death. Those mice
susceptible to KA administration show an excitotoxic
response similar to what has been described in rats
[18,30-32].
Metabolic disturbances are often associated with epi-
leptic seizures, but the pathogenesis of this relationship
is poorly understood. The importance of glucose balance
has been identified in studies demonstrating that epilep-
tic seizures can be exacerbated under conditions of
hyper- or hypoglycemia [33-35]. Studies of type I
and type II diabetic subjects have found that diabetes-
related seizures usually improve with control of glycemic
status [36]. In particular, the treatment of choice for
hyperglycemia-related seizures is glycemic control, and
seizures are usually resistant to antiepileptic drugs if
blood glucose is not brought under control [37]. At
present, the mechanisms underlying glucose regulation
and altered neuronal excitability remain incompletely
understood [38]. Nevertheless, despite the reported asso-
ciation between blood glucose levels and certain epilepsy
syndromes [39], few studies to date have evaluated the
efficacy of controlling blood glucose levels on seizure-
induced neuronal injury.
In this study, we used mice that possess strain-
specific gene products that can modify vulnerability toexcitotoxin-induced cell death [27]. We were interested
in identifying the relationship between glycemic index
and susceptibility to seizure-induced excitotoxic cell
death and establishing whether modulation of glycemic
index could modify the susceptibility to epilepsy. As
a first step, we wanted to determine if glucose adminis-
tration following kainate-induced SE could reduce
seizure-induced cell death in mice susceptible to
excitotoxin-induced cell loss (FVB/N). Secondly, we
wanted to determine if modulation of the glycemic
index, in models of hypoglycemia or hyperglycemia,
could affect seizure susceptibility and its neuropatho-
logical consequences following kainate administration
in a mouse strain previously found to be resistant to
seizure-induced cell death (C57BL/6).
Results
Seizure effects following systemic administration
of kainate
Kainic acid (KA) is a selective glutamate receptor
agonist and potent neurotoxin that when injected
systemically, produces epileptic behavior and subse-
quent neurodegeneration [21,22]. As previously reported
[18,27,40], administration of KA caused characteristic
sequential behavioral changes. Within 15 minutes after
KA injection, all animals began to exhibit behavioral
signs of convulsive seizures. Seizure behavior was char-
acterized by forelimb clonus and hindlimb clonus within
20–30 minutes after injection. Within 40–45 min after
injection, all mice exhibited continuous tonic-clonic
seizures that lasted for 1–2 hr. As shown in Table 1, we
did not observe any strain-dependent differences in the
percentage of mice exhibiting status epilepticus (stage 5
seizures), latency to onset of severe (stage 4/5) seizures,
or duration of severe (stage 4/5) seizures.
Glucose infusion restores glycemic control following
KA-induced SE
Subcutaneous administration of KA at a dose of 20 mg/kg
of body weight into FVB mice resulted in a 2-fold reduc-
tion in blood glucose from 12 mM in vehicle-injected
controls to 6 mM when measured three hours following
administration (Figure 1). Interestingly, intraperitoneal
injection of 20 mg/ml glucose into FVB mice once a day
for 3 days following KA administration restored blood
glucose levels in mice to values similar to controls (FVB
mice, saline-treated), suggesting that exogenous adminis-
tration of glucose can protect against glucose dysregula-
tion following KA.
Glucose infusion protects mice against post-seizure
hippocampal pathology
As shown in Figure 2A, horizontal sections from FVB mice
sacrificed 7 days following kainate injection and processed
Table 1 Effect of kainic acid administration on seizure parameters in normoglycemic, hypoglycemic and hyperglycemic
mice








FVB/NJ Normoglycemic 100 96.37 32.8 ± 1.6 69.6 ± 4.7
C57BL/6 Normoglycemic 100 93.76 30.5 ± 1.3 76.3 ± 2.8
C57BL/6 Hypoglycemic 100 89.34 30.4 ± 6.4 55.4 ± 14.4
C57BL/6 Non-ketotic hyperglycemic 100 92.58 49.6 ± 6.1a 66.2 ± 4.0
C57BL/6 STZ-hyperglycemic 100 96.08 36.5 ± 4.6 93.3 ± 2.9b
KA induced a similar level of stage, latency and seizure duration irrespective of mouse strain. A significant difference in latency to onset of stage 4 seizures was
observed in non-ketotic hyperglycemic mice as compared to normoglycemic C57BL/6 mice (aF=7.50; P=0.03) and a significant difference in duration of stage 4/5
seizures was observed in STZ-hyperglycemic mice as compared to normoglycemic C57BL/6 mice (bF=17.56; P=0.006).
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confirmed that administration of KA led to the degener-
ation and loss of CA3 and CA1 pyramidal neurons and
dentate hilar neurons, as evidenced by a loss of cresyl
violet staining and NeuN-immunostaining (Figure 2A,
panels D,E). In accordance with previous studies
[30,32,41,42], cells within the dentate granule cell layer
and area CA2 of Ammon’s horn were spared. In con-
trast, representative sections from glucose-treated mice
showed a dramatic reduction in the extent of cell loss
throughout all hippocampal cell fields. In particular, FVB
mice administered glucose following KA-induced SE
exhibited no detectable reduction of neurons within the
hippocampus proper (Figure 2A, panels G,H), and no
indication was noted of damage to neuronal nuclei in
any hippocampal region or in the septum, amygdala,Figure 1 Blood glucose concentrations following KA and
following glucose treatment. Blood glucose concentrations
measured 3 hours following kainate-induced seizures and 24 hours
following an injection of 1 ml of 20% glucose. Note that acute
glucose treatment restored blood glucose concentrations to near
baseline levels, while kainate administration resulted in a seizure-
associated decrease in blood glucose concentration. Data represent
the mean ± S.E.M. of at least 5 mice per condition. Asterisk indicates
significant difference compared with any other group (ANOVA with
post hoc Student Newman Keuls; F=23.61, P<0.001).pyriform cortex, neocortex, or thalamic nuclei. Our
results suggest that the protection against excitotoxic cell
death by the relatively small dose of glucose results from
glycemic control after KA.
In accordance with previous studies [23,27], quantita-
tive analysis of subfield group means revealed that mice
susceptible to seizure-induced cell death via KA admin-
istration (FVB) displayed a reduction of 44% dentate
hilar neurons, 64% of CA3 pyramidal neurons, and 49%
of CA1 pyramidal neurons seven days after KA adminis-
tration (F=17.72 ; P<0.001; Figure 2B). In contrast, ad-
ministration of glucose significantly reduced neuronal
damage in FVB mice (F=16.38; P<0.001). Post hoc anal-
yses revealed a dramatic protective effect of glucose fol-
lowing KA administration in area CA3 (p<0.001), area
CA1 (p<0.001); and the dentate hilus (p< 0.001), as com-
pared to FVB mice treated with KA alone.Effect of hypoglycemia on blood glucose concentration
and kainate-induced seizure severity
Our data confirms previous studies [43,44] showing
that hypoglycemia (induced by bolus insulin adminis-
tration) significantly modulated glucose levels. Blood
glucose levels following bolus injection of insulin were
significantly lower by nearly 2-fold as compared to
baseline normo-glycemic levels in B6 mice (Figure 3A).
As well, blood glucose levels measured 3 hours
following bolus insulin administration and kainate
administration were also significantly lower than cor-
responding values in normoglycemic B6 mice without
kainate administration.
To determine if hypoglycemia could modulate seizure
severity, B6 mice were treated with kainic acid and
seizure severity was assessed. As shown in Table 1, we
found no difference between B6 mice that were hypo-
glycemic versus vehicle injected mice with regard to
seizure sensitivity, as evidenced by no alterations in
latency to onset of first severe seizure (P=0.990) or dur-
ation of severe seizures (P=0.24). Thus, hypoglycemia
was without effect on KA-induced seizure activity.
Figure 2 Glucose infusion suppresses neuronal damage following kainate-induced status epilepticus. (A) Low-magnification
photomicrographs of cresyl violet (A,D,G) and NeuN-immunofluorescent (B,E,F) stained horizontal sections of the hippocampus
illustrating surviving cells throughout the hippocampus 7 days following systemic kainate administration to FVB mice. High-magnification
NeuN-immunofluorescent stained horizontal sections of area CA3 (C,F,I) among the three groups. Neuron loss following status epilepticus was
profoundly reduced when exogenous glucose was administered for 3 consecutive days following seizure induction. Note the significant
amount of cell loss in representative sections from KA-treated mice in the dentate hilus, area CA3 and area CA1, depicted as an absence of
cresyl violet stain (D) or NeuN-immunofluorescence (E). Cell loss was not observed after post-seizure glucose infusion (G,H,I). CA1 and CA3 denote
the hippocampal subfields; H, dentate hilus. Scale bar = 750 μm (A,C); 100 μm (B,D). High-magnification photomicrographs represent details of
the boxed area of CA3 shown in B. (B) Quantitative analysis of neuronal density in hippocampal subfields seven days following KA administration
to FVB mice. Viable surviving neurons were estimated by cresyl violet staining. Bars denote the percentage of surviving neurons
(as compared with saline-injected sham control FVB mice). Data represent the mean ± S.E.M. of at least 5 mice per condition. Asterisks indicate
significant difference compared with KA alone or Sham control of P<0.05. (ANOVA with post hoc Student Newman Keuls; a: F=9.68, P=0.003; b:
F=42.87, P<0.001; c: F=23.76, P<0.001).
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neurodegeneration
Following systemic administration of KA to young adult
B6 mice, essentially no cell death was observed within
the hippocampus or within any other region of the
brain, in accordance with previous results [23,27], and as
evidenced by no loss of cresyl violet or NeuN-
immunostaining (Figure 3C, panels D,E). In contrast, inB6 mice with insulin-induced hypoglycemia followed by
KA-induced SE, we observed significant cell loss, as evi-
denced by decreased cresyl violet (Figure 3C, panel G)
and NeuN-immunostaining in three hippocampal sub-
fields (dentate hilus, area CA3 and area CA1; Figure 3C,
panel H).
In particular, quantitative analysis of subfield group
means revealed that hypoglycemic B6 mice that underwent
Figure 3 Glucose infusion suppresses neuronal damage following kainate-induced status epilepticus damage. (A) Blood glucose
concentration was decreased significantly 3 hours after insulin injection and after insulin + kainate injections. Data represent the mean ± S.E.M. of
at least 5 mice per condition. Asterisk indicates significant difference compared with any other group (ANOVA with post hoc Student Newman
Keuls; F=16.57, P<0.001). (B) Quantitative analysis of neuronal density in hippocampal subfields following insulin injection + KA to B6 mice. Viable
surviving neurons were estimated by cresyl violet staining. Bars denote the percentage of surviving neurons (as compared with saline-injected
sham control B6 mice). Data represent the mean ± S.E.M. of at least 5 mice per condition. Asterisks indicate significant difference compared with
KA alone or Sham control (ANOVA with post hoc Student Newman Keuls; F=99.70, P<0.001). (C) Insulin-induced hypoglycemia dramatically
increased the extent of hippocampal cell death in B6 mice. Low-power photomicrographs of cresyl violet (A,D,G) and NeuN-stained (B,E,H)
horizontal sections of the hippocampus showing differential cell loss 7 days after kainate-induced SE in a normoglycemic (NS + KA) and
hypoglycemic (insulin + KA) mouse. Note that extensive kainate-induced cell loss, as evidenced by loss of cresyl violet staining (G) and NeuN
immunostaining (H), is only observed in the dentate hilus, areas CA3 and CA1 following insulin pre-treatment in excitotoxin cell death resistant
(B6) mice. CA1 and CA3 denote the hippocampal subfields; H, dentate hilus. Scale bar = 750 μm (A,C); 100 μm (B,D). High-magnification
photomicrographs represent details of the boxed area of CA3 shown in B.
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dentate hilar neurons, over 80% of CA3 pyramidal neu-
rons, and nearly 70% of CA1 pyramidal neurons
(Figure 3B). Thus, a significant reduction in hippocampal
neurons within the dentate hilus (F=64.31; P<0.001), area
CA3 (F=150.33; P<0.001) and area CA1 (F=99.70;
P<0.001) was observed. In contrast, normoglycemic B6
mice that underwent KA-induced SE displayed no
detectable evidence of reduction of neurons in any of
the hippocampal subfields after KA administration.
These results demonstrate that B6, which are typically
excitotoxin cell death resistant, exhibit seizure-induced
cell death when they undergo insulin-induced hypo-
glycemia followed by KA-induced SE.Effects of STZ-induced diabetes and hyperglycemia on
blood glucose concentration
Diabetes was induced by streptozotocin (STZ), a
glucosamine-nitrosourea compound that damages pan-
creatic ß cells, resulting in hypoinsulinemia and hyper-
glycemia [45]. Three weeks after the streptozotocin
injection, more than 90% of mice injected with STZ
developed diabetes shortly after injection with tail blood
glucose concentrations higher than 25 mM . The ele-
vated blood glucose persisted and worsened throughout
the study with diabetic B6 mice having an average blood
glucose of 37 ± 1.56 mM (Figure 4). Similarly, mice thatFigure 4 Blood glucose concentrations following STZ and
non-ketotic hyperglycemia in B6 mice. Streptozocin (STZ) diabetic
mice developed full diabetes with blood glucose concentrations
greater than 30 mM. An acute glucose injection was used as a
non-STZ model of hyperglycemia. Note that there was no significant
difference in blood glucose concentration between the two models
of hyperglycemia prior to kainate administration. Data represent the
mean ± S.E.M. of at least 5 mice per condition. Asterisk indicates
significant difference (ANOVA with post hoc Student Newman Keuls;
F=105.54, P<0.001).received a bolus injection of 20% glucose to create a
condition of nonketotic hyperglycemia independent of
diabetes also displayed elevated blood glucose concen-
trations that were significantly different from normo-
glycemic mice (Figure 4; F=195.54; P<0.001). Injections
of citric acid (vehicle) produced no diabetes; glucose
concentrations were 13.2 ± 0.5 mM.
Diabetic hyperglycemia and non-ketotic hyperglycemia
modulate seizure sensitivity
Previous studies have suggested that glycemic modula-
tion can alter seizure threshold [44,46]. Thus, in the
present study, we used two models of hyperglycemia to
assess the effects of glycemic modulation on seizure
induction and seizure duration in B6 mice. While we
found no qualitative differences in seizure intensity irre-
spective of the model utilized to induce hyperglycemia
(no differences in the percentage of mice achieving sta-
tus epilepticus, Table 1), we did find differences between
the models with regard to latency to onset of stage 4
seizures (Table 1). In particular, we found a significant
increase in latency to onset of stage 4 seizures in our
model of hyperglycemia as compared to vehicle-injected
animals (KA=30.50 ± 1.32 mins vs. Hyperglycemia +
KA= 49.60 ± 6.06 mins, P=0.03), but no significant dif-
ference in latency when we compared STZ-induced
hyperglycemia vs. vehicle alone (P=0.25). As well, we
found significant differences in the duration of stage 4
seizures depending on our model of induction of hyper-
glycemia. While we found no significant differences in
seizure duration between hyperglycemic versus vehicle-
injected mice (P=0.09), we did find a significant differ-
ence in seizure duration when comparing STZ-induced
hyperglycemic mice versus controls (KA=76.25 ± 2.83 vs.
STZ + KA= 93.25 ± 2.90, P=0.006).
Diabetic hyperglycemia aggravates the extent of
seizure-induced cell death in C57BL/6 mice post-kainate
administration
Streptozotocin (STZ) is a ß-cytotoxic agent widely used
to induce diabetes in rodents [47,48]. The STZ model
has been used extensively in studies in the patholophy-
siology of diabetes and its complications [49,50]. We
examined differences in status-induced neuronal injury
in B6 mice treated with vehicle and kainate alone with
those that exhibited STZ-induced diabetes. As shown in
Figure 5A, we found significant differences in the extent
of injury between these two groups when cell death was
measured 7 days later. Consistent with our previous
studies [23,27], irrespective of the hippocampal area
examined, administration of KA to nearly excitotoxin-
resistant mice (B6) resulted in no detectable reduction
in hippocampal neurons within any subfields of the
hippocampus proper (Figure 5A, panels D,E,F). In
Figure 5 Diabetic-induced hyperglycemia aggravates status epilepticus-induced hippocampal damage. (A) Low-power photomicrographs
of cresyl violet (A,D,G) and NeuN-immunofluorescent-stained (B,E,H) horizontal sections of the hippocampus illustrating surviving cells throughout
the hippocampus 7 days following systemic kainate administration to vehicle-treated, and STZ-treated mice that underwent
KA-induced SE. STZ-induced hyperglycemia dramatically increased the extent of hippocampal cell death in excitotoxin cell death resistant B6
mice. Note the significant amount of cell damage in representative sections from STZ + KA treated mice as evidenced by a loss of cresyl violet
staining (G) and NeuN-immunofluorescence (H) and complete absence of any seizure-associated cell loss in KA treated mice (D,E). CA1 and
CA3 denote the hippocampal subfields; H, dentate hilus. Scale bar = 750 μm (A,C); 100 μm (B,D). High-magnification photomicrographs
represent details of the boxed area of CA3 shown in B. (B) Quantitative analysis of neuronal density in hippocampal subfields seven days
following STZ + KA administration to B6 mice. Viable surviving neurons were estimated by cresyl violet staining. Bars denote the percentage
of surviving neurons (as compared with saline-injected sham control B6 mice). Data represent the mean ± S.E.M. of at least 5 mice per condition.
Asterisks indicate significant difference compared with KA alone or Sham control of P<0.05. (ANOVA with post hoc Student Newman Keuls;
F=195.54, P<0.001).
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mice led to the profound neuronal loss of dentate hilar,
area CA3 and area CA1 cells, as evidenced by a loss of
cresyl violet staining (Figure 5A, panel G) and NeuN-
immunofluorescence (Figure 5A, panels H,I).
Quantitative analysis of hippocampal subfield group
means (Figure 5B) revealed a significant reduction in
neuronal cell loss within the dentate hilus (F=23.28;
P<0.001), area CA3 (F=64.73; P<0.001) and area CA1
(F=112.57; P<0.001) of diabetic hyperglycemic micethat underwent KA-induced SE. Thus, we found that
compared with non-diabetic mice, diabetic mice lost
more hippocampal neurons during the acute stage
after status epilepticus. In contrast, we observed no sig-
nificant cell loss in B6 mice that were injected with
vehicle prior to KA-induced SE. These results demon-
strate that B6, which are typically excitotoxin cell death
resistant, exhibit seizure-induced cell death when they
undergo diabetes-induced hyperglycemia followed by
KA-induced SE.
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seizure-induced cell death in C57BL/6 mice post-kainate
administration
As shown in Figure 6A, systemic administration of KA
to normoglycemic B6 mice was without effect on the in-
duction of any cell loss throughout any hippocampal
subfields (panels D,E,F). C57BL/6 mice showed no
detectable reduction of neurons in the following hippo-
campal areas: dentate hilus, area CA3, area CA1, and
the dentate granule cell layer; nor to neuronal nuclei in
the septum, amygdala, pyriform cortex, neocortex or
thalamic nuclei. These results are in accordance with pre-
viously obtained results [23,27]. In contrast, diabetic miceFigure 6 Hyperglycemia aggravates status epilepticus-induced hippo
(A,D,G) and NeuN immunofluorescent-stained (B,E,H) horizontal sections of th
7 days following systemic kainate administration to normoglycemic and non
Hyperglycemia dramatically increased the extent of hippocampal cell death i
of cell loss, as evidenced by a loss of cresyl violet staining (G) and NeuN imm
KA-treated mice throughout all excitotoxin cell death susceptible regions (G,H
resistant mice (D,E). CA1 and CA3 denote the hippocampal subfields; H, dent
photomicrographs represent details of the boxed area of CA3 shown in B. (B
following hyperglycemia + KA to B6 mice. Viable surviving neurons were est
surviving neurons (as compared with saline-injected sham control B6 mice). A
Sham control of P<0.05. (ANOVA with post hoc Student Newman Keuls; a: F=that underwent KA-induced SE displayed a reduction of
hippocampal neurons in areas CA3, and CA1 and within
the dentate hilus, as seen by a loss of cresyl violet staining
(Figure 6A, panel G) or NeuN immunofluorescence
(Figure 6A, panels H,I).
Quantitative analyses of hippocampal neuron numbers
showed a dramatic and significant reduction on average of
90% of dentate hilar neurons (F=781.34; P<0.001), CA3
pyramidal neurons (F=542.49; P<0.001), and CA1 pyram-
idal neurons (F=567.89; P<0.001) 7 days after KA adminis-
tration as compared with normoglycemic mice (Figure 6B).
These results indicate that glycemic modulation can induce
differential vulnerability of neurons in the hippocampus.campal damage. (A) Low-power photomicrographs of cresyl violet
e hippocampus illustrating surviving cells throughout the hippocampus
-ketotic hyperglycemic mice that underwent KA-induced SE.
n excitotoxin cell death resistant B6 mice. Note the significant amount
unofluorescence (H), in representative sections from hyperglycemic
,I) and absence of cell loss in KA-treated excitotoxin cell death
ate hilus. Scale bar = 750 μm (A,C); 100 μm (B,D). High-magnification
) Quantitative analysis of neuronal density in hippocampal subfields
imated by cresyl violet staining. Bars denote the percentage of
sterisks indicate significant difference compared with KA alone or
781.34; P<0.001; b: F=542.49; P<0.001; c: F=567.89; P<0.001).
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The effects of glycemic modulation on excitotoxic cell
death and seizure susceptibility are diverse and complex.
It has previously been established that limited energy
availability compromises hippocampal neuronal viability
during status epilepticus [51-53]. As seizure-induced
excitotoxic cell death is likely due to excessive glutamate
release and excessive cytosolic calcium [54], these can
be worsened by energy failure. In particular, intracel-
lular sequestering of Ca2+ and the concomitant trans-
membrane extrusion of Ca2+ are directly or indirectly
ATP-dependent [55], and can result in impaired ATP
production [56], the release of reactive oxygen species
[57], and the subsequent release of proteins involved in
the cell death cascade [58-61]. As a result, many of the
steps mediating seizure-induced excitotoxic cell death
are sensitive to energy availability. In the present study,
we examined the effects of glycemic modulation on exci-
totoxic cell death and seizure susceptibility following
systemic administration of the chemoconvulsant, kainic
acid to inbred strains of mice. We demonstrated that
injection of glucose following KA-induced SE was pro-
foundly neuroprotective against seizure-induced neur-
onal damage. As well, we also found that compared
with normoglycemic mice, (1) hyperglycemic were less
seizure sensitive, (2) diabetic hyperglycemic mice were
more seizure sensitive, and (3) hypo-, hyper- or STZ-
hyperglycemic mice showed increased susceptibility to
seizure-induced cell death after status epilepticus.
Glycemic control is neuroprotective in CNS injury
In order to assess the putative ‘neuroprotective’ effects
of controlling glycemic status in mice that underwent
KA-induced SE, we administered glucose 3 hours fol-
lowing KA-induced status epilepticus and then gave
two additional injections 24 and 48 hours following
the initial glucose injection. We report that FVB mice
are hypoglycemic following KA-induced SE and that
glucose treatment reverses the hypoglycemic status as
well as provides protection against seizure-induced cell
death. Our results are in agreement with previous clin-
ical and experimental studies on ischemic brain injury
[62]. Preclinical data from animal models indicates
that insulin may reduce damage in both global and
focal ischemia [62,63] and in transient global ischemia,
insulin has a direct neuroprotective effect on CNS par-
enchyma [64]. Moreover, Nagamizo et al. [65] demon-
strated that a relatively small dose of preischemic insulin
protects against ischemic spinal cord injury, and that the
protective effect was cancelled by a concomitant glucose
infusion. The idea of brain protection by insulin is
not new; however, the mechanisms underlying glucose
levels and altered neuronal excitability remain incom-
pletely understood.Seizure susceptibility and glycemic control
As previous studies have established that there is a
biphasic dependence of seizure susceptibility on blood
glucose concentrations, we examined several seizure
parameters (seizure intensity, seizure latency and seizure
duration) in hypoglycemic and hyperglycemic B6 mice.
While we found no difference between B6 mice that
were hypoglycemic versus vehicle-injected mice with
regard to seizure sensitivity, latency to onset of first
severe seizure or duration of severe seizures, we did
observe that hyperglycemia can modulate seizure sus-
ceptibility. In particular, while we found no qualitative
differences in seizure intensity irrespective of the model
utilized to induce hyperglycemia, we did find differences
between the models with regard to latency and duration.
Interestingly, hyperglycemic mice that underwent KA-
induced SE demonstrated a significant increase in the
latency to onset of severe seizures, suggesting a reduc-
tion in seizure severity. In contrast, STZ mice displayed
a significant increase in seizure duration following KA-
induced SE, indicative of an increase in seizure sensitiv-
ity. Thus, depending on the model of hyperglycemia
utilized, B6 mice appeared to be either less seizure sensi-
tive (hyperglycemia) or more seizure sensitive (STZ-
induced hyperglycemia). While no studies to date have
compared seizure susceptibility differences based on the
model of hyperglycemia, previous studies have found
that STZ-induced diabetic rats that underwent lithium-
pilocarpine induced SE had a higher seizure susceptibil-
ity than normoglycemic rats [66].
It is somewhat surprising that we saw differential
effects on seizure susceptibility depending on the model
of hyperglycemia utilized in our studies, as others have
demonstrated that seizure susceptibility has been shown
to increase with incremental blood glucose, either during
experimental diabetes or acute hyperglycemia [38,67].
One potential reason for the discrepancy between our
models of hyperglycemia could be the result that we
compared a bolus injection of glucose to create a condi-
tion of nonketotic hyperglycemia independent of dia-
betes versus the STZ-induced model of type 1 diabetes
(chemical ablation of the pancreatic ß cells; [68]). The
underlying mechanism for the difference in seizure
susceptibility between the high glucose model and STZ
model is uncertain, although the high glucose model has
been described as an acute hyperglycemia model, while
the STZ model is described as a chronic or sustained
hyperglycemia model.
Hypoglycemia mice show increased KA-induced
hippocampal degeneration
Previous studies in our laboratory have demonstrated
robust strain differences with respect to susceptibility
to excitatory amino acid-induced cell death [26-28].
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exhibit comparable seizure activity following systemic
administration of kainic acid, FVB mice have been
reported to be vulnerable to excitotoxic insults, while B6
mice are resistant to excitotoxic cell death. While the
molecular and cellular events responsible for the select-
ive vulnerability of hippocampal neurons to kainic acid
are not yet fully understood, excitotoxicity is thought to
be triggered by the activation of ionotropic glutamate
receptors resulting in calcium dysregulation [22,54,69],
oxidative stress and mitochondrial dysfunction, and the
initiation of signaling cascades within susceptible neu-
rons resulting in cell death [70,71].
Our results demonstrate that hypoglycemia induced a
phenotypic switch in B6 mice, previously characterized
as resistant to seizure-induced excitotoxic cell death. In
particular, B6 (excitotoxin cell death resistant) mice with
insulin-induced hypoglycemia following by KA-induced
SE exhibited greater seizure-induced cell death. We are
not aware of any studies that compared the effects of
hypoglycemia on status epilepticus associated injury.
However, our results suggest that hypoglycemia aggra-
vates excitotoxic neuronal death in a nearly excitotoxin-
resistant brain.
The mechanism of hypoglycemia-induced injury is
thought to be the result of several contributing factors
acting downstream of glucose deprivation, and not just a
loss of energy supply (e.g. glucose) from neurons [72].
One of these contributing factors includes the sustained
activation of glutamate receptors [73], as well as
increased mitochondrial membrane permeability [74].
Differences in the number and function of neurotrans-
mitter receptors, molecular and biochemical pathways of
energy metabolism and/or susceptibility to respiratory
depression may also be responsible for the increased
vulnerability to excitotoxic cell death. At present, while
we cannot explain why induction of hypoglycemia prior
to KA-induced SE renders mice previously characterized
as excitotoxin cell death resistant to become susceptible;
it is possible that excessive glutamate activation (via
acute hypoglycemia combined with stimulation of iono-
tropic glutamate receptors via kainate administration)
drives glutamate release to excessive levels that cannot
be resolved when only one insult is presented. Add-
itional studies must clarify the specific cellular mechan-
isms that promote neurotoxicity in C57BL/6 mice.
Hyperglycemia aggravates the extent of KA-induced
cell death
In the present study, we found that STZ-induced and
glucose-induced hyperglycemia exacerbated the neu-
ropathological consequences of KA-induced SE in
excitotoxin-resistant mice. Thus, both acute and chronic
hyperglycemia produced the same outcome of increasedsusceptibility to seizure-induced excitotoxic cell death.
Our results demonstrating that both models of hypergly-
cemia rendered hippocampal neurons more vulnerable
to KA-induced excitotoxic cell death are in agreement
with previous clinical and animal studies. In particular,
previous studies have demonstrated that status epilepti-
cus and its associated neuropathological consequences is
not an uncommon complication associated with diabetic
hyperglycemia [33,35]. Diabetes has been suggested to
exacerbate status epilepticus-induced brain damage, re-
sult in poor recovery following status, and even increase
mortality [38,75,76]. Moreover, animal studies have
demonstrated that high glucose concentrations are
associated with an increased susceptibility to seizures
and augmented brain damage in the pilocarpine model
of temporal lobe epilepsy [66]. Hyperglycemia is known
to modify many proteins important for cell survival by
advanced glycation, inducing some death-related pro-
teins like high mobility group box 1, which triggers the
expression of pro-inflammatory mediators, or downregu-
lation of cytoskeletal proteins that support neuronal cell
survival [77,78]. Thus, the prolonged effects of hypergly-
cemia may be the result of an additive effect of toxicity
on the brain.
Conclusion
In summary, we found that glycemic control could res-
cue hippocampal cells from seizure-induced excitotoxic
cell death in an excitotoxin-susceptible mouse strain,
FVB. As well, the results presented here illustrate that
hyper- or hypoglycemia additively increased the extent
of seizure-induced cell death in an excitotoxin-resistant
mouse strain, B6. The ability of glucose dysregulation to
elicit a phenotypic switch from excitotoxin resistant
to susceptible after kainate administration implicates
glucose dysfunction as a key event in the pathogenesis of
seizure-induced excitotoxic cell death. While the specific
pathophysiological mechanisms underlying this relation-
ship remain unclear, our data support the hypothesis
that deficient insulin signaling may represent a critical
contributing factor in the susceptibility to seizure-
induced cell death and this may be an important thera-
peutic target. An understanding of the interplay between
glucose regulation and excitotoxic neurodegeneration
will have important consequences, not only in the con-
text of epilepsy, but for hypoxia, stroke, and other
related pathologies.
Methods
All experiments were conducted in accordance to the
guidelines set forth by the National Institutes of Health.
All procedures were approved by the University of
Southern California Institutional Animal Care and Use
Committee. Animals were housed under controlled
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water were provided to the mice ad libitum.
Animals
Four separate cohorts of mice were used for these stud-
ies. Six to eight-week old FVB/N male mice (Jackson
Laboratories, Bar Harbor, ME), housed in groups of 4–5
per cage, were used for the KA + exogenous glucose
experiments. Three separate cohorts of six to eight-week
old C57BL/6 (Jackson Laboratories, Bar Harbor, ME),
housed in groups of 4–5 per cage, were used for the
hypoglycemia + KA, hyperglycemia + KA, and Strepto-
zotocin (STZ) + KA experiments. All of the procedures
used in these experiments were in accordance with the
NIH Guide and approved by the USC Animal Care
and Use Committee. All efforts were made to min-
imize the number and suffering of any animals used in
these experiments.
Induction of hypoglycemia
On the experimental day, mice were weighed and the
baseline blood glucose was measured. Mice were
injected i.p. with 1 I.U./kg of regular human insulin
(Humalin, Eli Lilly, Indianopolis, IN), freshly dissolved in
normal saline. Blood glucose from blood was measured
prior to insulin administration (basal glucose concentra-
tion), and at 2 additional timepoints. Blood glucose was
measured 30 minutes following insulin administration,
prior to kainate administration and 3 hours following
kainate administration. Mixed peripheral blood (arterial,
venous, and capillary) samples were obtained after snip-
ping the tip of the tail. A droplet of blood (~2 μl) was
collected on the test strip and evaluated using a One-
Touch Glucosemeter (LifeScan, Millipitas, CA). As the
sample size of the blood droplet was minimal, there was
no adverse effect to the well being of the mouse and
only a single cut of the tip of the tail was needed to pro-
vide all samples. Blood glucose levels of <5.1 mM were
defined as hypoglycemic.
Induction of hyperglycemia
One group of mice from each strain was fasted over-
night and intraperitoneally injected with 1 ml of a 20%
glucose solution 30 minutes prior to KA-induced SE
to create a condition of nonketotic hyperglycemia inde-
pendent of diabetes [38]. Blood glucose from blood was
measured prior to glucose administration (basal glucose
concentration) and 3 hours following kainate administration.
A second group of mice was fasted overnight and
administered 200 mg/kg, i.p. streptozotocin (STZ;
Sigma Aldrich, St. Louis, MO) in 100 mM citrate buffer
(pH 4.5), an antibiotic that destroys the insulin-secreting
ß cells of the pancreas [47,48] and has previously been
used to induce chronic hypoinsulinemia in rodents[49,50]. Controls received citrate buffer alone. Both sets
of mice underwent kainate-induced status epilepticus
three weeks following drug administration. Blood glu-
cose was measured prior to STZ administration (basal
glucose concentration), and monitored weekly following
STZ administration (for a total of 3 weeks) in peripheral
blood obtained after snipping the tail. A droplet of blood
(~2 μl) was collected on the test strip and evaluated
using a One-Touch Glucosemeter (LifeScan, Millipitas,
CA). Mice with blood glucose values > 250 mg/dl were
included in the STZ group.
Kainate-induced status epilepticus
Sustained seizures (status epilepticus) were induced in
animals by the administration of kainic acid (KA), a
potent agonist of the AMPA/KA class of glutamate
receptors. KA was dissolved in isotonic saline (pH 7.4)
and administered subcutaneously to adult mice at a dose
of 20 mg/kg (Nanocs, New York, NY). Following KA
administration, mice were monitored continuously for
4 h for the onset of locomotor activity and behavioral
manifestations of limbic seizure episodes, as described
previously [23-26,28]. Status epilepticus was defined as
continuous behavioral seizure activity lasting at least
1 hour or a series of intermittent seizures without res-
toration of normal behavioral patterns between succes-
sive seizures. Mice were scored for seizure activity using
a previously defined six-point seizure scoring scale [27]
that was adapted from a five-point scale for rats [79].
Seizure stages were defined as follows: Stage 1, immo-
bility; Stage 2, forelimb and/or tail extension, rigid pos-
ture; Stage 3, repetitive movements, head bobbing; Stage
4, rearing and falling; Stage 5, continuous rearing and
falling; and Stage 6, severe tonic-clonic seizures. Only
those mice exhibiting at least 45 min of continuous stage
4/5 seizures were included in this study, as previous
studies have suggested that there is a direct relationship
between the generation of epileptiform activity and the
extent of damage in hippocampal subfields [18,32,80].
Seizure parameters monitored included latency of con-
vulsions and duration of severe (Stage 4/5) seizure activ-
ity. All experiments were approved by the Institutional
Animal Care and Use Committee (IACUC) of the Uni-
versity of Southern California and conducted in accord-
ance with its guidelines. Every effort was made to
minimize animal suffering and to minimize the number of
animals utilized in order to produce reliable scientific data.
Administration of 20% glucose after KA-induced SE
Administration of 1 ml of 20 mg/ml glucose (intraperi-
toneal) was initiated 3 hours following KA-induced
status epilepticus and two additional injections were
given 24 and 48 hours following the initial glucose injec-
tion. Blood glucose from blood was measured prior to
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Tissue preparation and histology
In order to evaluate the severity of kainate-induced exci-
totoxic brain damage, brains from each strain of mice
were processed for light microscopic histopathologic
evaluation according to previously published methods
[29]. Briefly, 7 days after seizure induction by kainate,
mice were anesthetized with Avertin and transcardially
perfused with 4% paraformaldehyde in 0.1M phosphate
buffer (pH 7.4). Brains were removed and post-fixed
overnight, followed by cryoprotection in 30% sucrose for
at least 12–18 h. Horizontal (40 μm) frozen sections
were cut on a sliding microtome and collected as free-
floating sections in 0.1M phosphate buffer (pH 7.4) until
processed for light microscopic histology. Every sixth
section (~240 μm) was processed for cresyl violet stain-
ing to assess cell loss and morphology.
NeuN immunofluorescence
Immunofluorescence was performed on an additional
series of sections (every sixth section; ~240 μm) to
detect those neurons that survived 7 days following
kainate-induced SE. For immunofluorescent labeling,
sections were washed with 0.1M phosphate buffer
(pH 7.4) and blocked with 5% normal serum and 0.1%
Triton X-100 in 0.1M phosphate buffer (pH 7.4). Next,
sections were incubated overnight with a neuronal mar-
ker against NeuN (monoclonal from mouse; Millipore,
Billarica, MA; 1:500) at 4°C. After several washes, sec-
tions were incubated with a secondary antibody from
mouse conjugated with Cy2 (1:200; Jackson Immuno-
Research, West Grove, PA) for 2 h at room temperature.
After rinsing, sections were mounted and coverslipped
with ProLong anti-fade mounting medium (Molecular
Probes, Eugene, OR). For labeling, omission of the pri-
mary antibody served as negative control. Labeling for
NeuN was viewed under an Olympus BX51 fluorescence
microscope (Olympus, New York, NY).
Quantitative analysis of hippocampal cell loss
Subsequently, to determine the susceptibility of indi-
vidual hippocampal subfields to neurotoxic insult, we
counted neurons in Nissl-stained sections. Quantitative
analysis of hippocampal cell loss was performed by an
observer blinded to the strain groups using unbiased
stereological methods on cresyl violet-stained sections
according to previously published protocols [23,27,28].
The Nissl-stained neurons in area CA3, area CA1, the
dentate hilus, and the dentate gyrus were counted in
both the right and left hippocampus and counting was
initiated within the ventral hippocampus at the first
point where hippocampal subfields could be easilyidentified. This level corresponded to horizontal section
54, based on the atlas of Sidman et al. [81]. Hippocampal
subfields were based on Franklin and Paxinos [82] classi-
fication and discrimination between the CA3 and the
dentate hilus region was based on morphological fea-
tures and locations of the cells [83,84]. Specifically, for
dentate hilar cell counts, the hilus was operationally
defined as the region bordered by the supra- and infra-
pyramidal granule cell layers and excluding the densely
packed pyramidal neurons of area CA3.
Neuron counts were made in all subfields and the
numbers for each side were averaged into single values
for each animal. Surviving cells were counted only if
they were contained within the pyramidal cell layer, den-
tate hilus or dentate gyrus, possessed a visible nucleus
and characteristic neuronal morphology and had a cell
body larger than 10 μm. Six square counting frames
(200 X 200 μm) were randomly placed in the pyramidal
layer of fields CA1 and CA3 or in the dentate gyrus
in 4–5 regularly spaced horizontal sections from each
animal. Two square counting frames were randomly
placed in the dentate hilus in 4–5 regularly spaced hori-
zontal sections from each animal. Neuronal nuclei were
evaluated at three different focal planes and only those
in the focal plane were counted with a 40X objective
and considered as a counting unit. Stereological analysis
was performed with the aid of ImagePro Plus 4.5 soft-
ware (Media Cybernetics, Silver Spring, MD) and a
motorized Z-stage (Optiscan; Prior Scientific, Fairfax,
VA). Final cell counts were expressed as the percent-
age of cells as compared to intact mice. Results were
assessed statistically by one-way analysis of variance
(ANOVA) using the computer program, SigmaStat
(Jandel Scientific, San Rafael, CA), and intergroup differ-
ences were analyzed by Newman-Keuls post hoc test.
Abbreviations
ANOVA, Analysis of variance; C57BL/6, B6; CNS, Central nervous system; FVB/
N, FVB; KA, Kainic acid; KA-SE, Kainate-induced status epilepticus; SE, Status
epilepticus; STZ, Streptozotocin; TLE, Temporal lobe epilepsy.
Authors’ contributions
PES conceived of the study, carried out the experiments, interpreted the
data, and drafted the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
This work was supported by NINDS RO1 NS380696. The author wishes to
thank Margaret Kornacki for technical assistance.
Received: 4 May 2012 Accepted: 24 July 2012
Published: 6 August 2012
References
1. Browne TR, Holmes GL: Epilepsy. New Engl J Med 2001, 344:1145–1151.
2. Chang BS, Lowenstein DH: Epilepsy. N Engl J Med 2003, 349:1257–1266.
3. Bien CG, Kurthen M, Baron K, Lux S, Helmstaedter C, Schramm J, Elger CE:
Long-term seizure outcome and antiepileptic drug treatment in
surgically treated temporal lobe epilepsy patients: a controlled study.
Epilepsia 2001, 42:1416–1421.
Schauwecker BMC Neuroscience 2012, 13:94 Page 13 of 14
http://www.biomedcentral.com/1471-2202/13/944. Cavazos JE, Jones SM, Cross DJ: Sprouting and synaptic reorganization
in the subiculum and CA1 region of the hippocampus in acute and
chronic models of partial-onset epilepsy. Neuroscience 2004,
126:677–688.
5. Babb TL, Brown WJ: Neuronal, dendritic, and vascular profiles of human
temporal lobe epilepsy correlated with cellular physiology in vivo. Adv
Neurol 1986, 44:949–966.
6. Wolf HK, Campos MG, Zentner J, Hufnagel A, Schramm J, Elger CE,
Wiestler OD: Surgical pathology of temporal lobe epilepsy. Experience
with 216 cases. J Neuropathol Exp Neurol 52, 52:499–506.
7. Engel J Jr, Babb TL, Crandall PH: Surgical treatment of epilepsy:
opportunities for research into basic mechanisms of human brain
function. Acta Neurochir Suppl 1987, 46:3–8.
8. DeLorenzo RJ, Pellock JM, Towne AR, Boggs JG: Epidemiology of status
epilepticus. J Clin Neurophysiol 1995, 12:316–325.
9. Fountain NB, Lothman EW: Pathophysiology of status epilepticus. J Clin
Neurophysiol 1995, 12:326–342.
10. Goulon M, Lévy-Alcover MA, Nouailhat F: Status epilepticus in the adult.
Epidemiologic and clinical study in an intensive care unit. Rev
Electroencephalogr Neurophysiol Clin 1985, 14:277–285.
11. Mathern GW, Cifuentes F, Leite JP, Pretorius JK, Babb TL: Hippocampal EEG
excitability and chronic spontaneous seizures are associated with
aberrant synaptic reorganization in the rat intrahippocampal kainate
model. Electroencephalogr Clin Neurophysiol 1993, 87:326–339.
12. Bouilleret V, Ridoux V, Depaulis A, Marescaux C, Nehlig A, Le Gal La Salle G:
Recurrent seizures and hippocampal sclerosis following
intrahippocampal kainate injection in adult mice:
electroencephalography, histopathology and synaptic reorganization
similar to mesial temporal lobe epilepsy. Neuroscience 1999,
89:717–729.
13. Davenport CJ, Brown WJ, Babb TL: Sprouting of GABAergic and mossy
fiber axons in dentate gyrus following intrahippocampal kainate in the
rat. Exp Neurol 1990, 109:180–190.
14. Nitecka L, Tremblay E, Charton G, Bouillot JP, Berger ML, Ben-Ari Y:
Maturation of kainic acid seizure-brain damage syndrome in the rat. II.
Histopathological sequelae. Neuroscience 1984, 13:1073–1094.
15. Olney JW, Collins RC, Sloviter RS: Excitotoxic mechanisms of epileptic
brain damage. Adv Neurol 1986, 44:857–877.
16. Sutula TP: Experimental models of temporal lobe epilepsy: new insights
from the study of kindling and synaptic reorganization. Epilepsia 1990,
31:S45–S54.
17. Coyle JT: Neurotoxic action of kainic acid. J Neurochem 1983, 41:1–11.
18. Ben-Ari Y: Limbic seizure and brain damage produced by kainic acid:
mechanisms and relevance to human temporal lobe epilepsy.
Neuroscience 1985, 14:375–403.
19. Nadler JV, Evenson DA: Use of excitatory amino acids to make axon-
sparing lesions of hypothalamus. Methods Enzymol 1983, 103:393–400.
20. Nadler JV, Perry VW, Cotman CW: Intraventricular kainic acid preferentially
destroys hippocampal pyramidal cells. Nature 1978, 271:676–677.
21. Schwob JE, Fuller T, Price JL, Olney JW: Widespread patterns of neuronal
damage following systemic administration of kainic acid: a histological
study. Neuroscience 1980, 9:991–1014.
22. Ben-Ari Y, Cossart R: Kainate, a double agent that generates seizures: two
decades of progress. Trends Neurosci 2000, 23:580–587.
23. Santos JB, Schauwecker PE: Protection provided by cyclosporin A against
excitotoxic neuronal death is genotype dependent. Epilepsia 2003,
44:995–1002.
24. Schauwecker PE: Seizure-induced neuronal death is associated with
induction of c-Jun N-terminal kinase and is dependent on genetic
background. Brain Res 2000, 884:116–128.
25. Schauwecker PE: Complications associated with genetic background
effects in models of experimental epilepsy. Prog Brain Res 2002,
135:139–148.
26. Schauwecker PE: Modulation of cell death by mouse genotype:
Differential vulnerability to excitatory amino acid-induced lesions. Exp
Neurol 2002, 178:219–235.
27. Schauwecker PE, Steward O: Genetic determinants of susceptibility to
excitotoxic cell death: implications for gene targeting approaches. Proc
Natl Acad Sci USA 1997, 94:4103–4108.
28. Schauwecker PE, Ramirez JJ, Steward O: Genetic dissection of the signals
that induce synaptic reorganization. Exp Neurol 2000, 161:139–152.29. Schauwecker PE, Williams RW, Santos JB: Genetic control of sensitivity to
hippocampal cell death induced by kainic acid: a quantitative trait loci
analysis. J Comp Neurol 2004, 477:96–107.
30. Nadler JV, Perry BW, Gentry C, Cotman CW: Degeneration of hippocampal
CA3 pyramidal cells induced by intraventricular kainic acid. J Comp
Neurol 1980, 192:333–359.
31. Nadler JV, Perry BW, Gentry C, Cotman CW: Loss and reacquisition of
hippocampal synapses after selective destruction of CA3-CA4 afferents
with kainic acid. Brain Res 1980, 191:387–403.
32. Sperk G, Lassmann H, Baran H, Kish SJ, Seitelberger F, Hornykiewicz O:
Kainic acid induced seizures: neurochemical and histopathological
changes. Neuroscience 1983, 10:1301–1315.
33. Huang CW, Hsieh YJ, Pai MC, Tsai JJ, Huang CC: Non-ketotic
hyperglycemia-related epilepsia partialis continua with ictal unilateral
parietal hyperperfusion. Epilepsia 2005, 46:1843–1844.
34. Kaufman FR: Diabetes in children and adolescents. Areas of controversy.
Med Clin North Am 1998, 82:721–738.
35. Singh BM, Strobos RJ: Epilepsia partialis continua associated with
nonketotic hyperglycemia: clinical and biochemical profile of 21
patients. Ann Neurol 1989, 8:155–160.
36. Chen JWY, Wasterlain CG: Status epilepticus: pathophysiology and
management in adults. Lancet Neurol 2006, 5:246–256.
37. Lavin PJ: Hyperglycemic hemianopia: a reversible complication of non-
ketotic hyperglycemia. Neurology 2005, 65:616–619.
38. Schwechter EM, Velisková J, Velisek L: Correlation between extracellular
glucose and seizure susceptibility in adult rats. Ann Neurol 2003,
53:91–101.
39. McCorry D, Nicolson A, Smith D, Marson A, Feltbower RG, Chadwick DW: An
association between type 1 diabetes and idiopathic generalized
epilepsy. Ann Neurol 2006, 59:204–206.
40. Lothman EW, Collins RC: Kainic acid induced limbic seizures: metabolic,
behavioral, electroencephalographic and neuropathological correlates.
Brain Res 1981, 218:299–318.
41. Ben-Ari Y, Tremblay E, Berger M, Nitecka L: Kainic acid seizure syndrome
and binding sites in developing rats. Brain Res 1984, 316:284–288.
42. Nadler JV, Cuthbertson GJ: Kainic acid neurotoxicity toward hippocampal
formation: dependence on specific excitatory pathways. Brain Res 1980,
195:47–56.
43. Chapman AG, Engelsen B, Meldrum BS: 2-Amino-7-Phosphonoheptanoic
acid inhibits insulin-induced convulsions and striatal aspartate
accumulation in rats with frontal cortical ablation. J Neurochem 1987,
49:121–127.
44. Kirchner A, Veliskova J, Velisek L: Differential effects of low glucose
concentrations on seizures and epileptiform activity in vivo and in vitro.
Eur J Neurosci 2006, 223:1512–1522.
45. Ito M, Kondo Y, Nakatani A, Hayashi K, Naruse A: Characterization of low
dose streptozotocin-induced progressive diabetes in mice. Environ Toxicol
Pharmacol 2001, 9:71–78.
46. Gastaut H, Lyagoubi S, Mesdjian E, Saier J, Ouahchi S: Generalized epileptic
seizures, induced by “non-convulsant” substances. I. Experimental study
with special reference to insulin. Epilepsia 1968, 9:311–316.
47. Mansford KR, Opie L: Comparison of metabolic abnormalities in
diabetes mellitus induced by streptozotocin or by alloxan. Lancet 1968,
1:670–671.
48. Rerup CC: Drugs producing diabetes through damage of the insulin
secreting cells. Pharmacol Rev 1970, 22:485–518.
49. Nakamura T, Terajima T, Ogata T, Ueno K, Hashimoto N, Ono K, Yano S:
Establishment and pathophysiological characterization of type 2 diabetic
mouse model produced by streptozotocin and nicotinamide. Biol Pharm
Bull 2006, 29:1167–1174.
50. Tesch GH, Allen TJ: Rodent models of sterptozotocin-induced diabetic
nephropathy. Nephrology 2007, 12:261–266.
51. Johansen FF, Diemer NH: Influence of the plasma glucose level on brain
damage after systemic kainic acid injection in the rat. Acta Neuropathol
1986, 71:46–54.
52. Meldrum BS: Metabolic factors during prolonged seizures and their
relation to nerve cell death. Adv Neurol 1983, 34:261–275.
53. Sapolsky RM, Stein BA: Status epilepticus-induced hippocampal damage
is modulated by glucose availability. Neurosci Lett 1989, 97:157–162.
54. Choi DW: Calcium and excitotoxic neuronal injury. Ann NY Acad Sci 1994,
747:162–171.
Schauwecker BMC Neuroscience 2012, 13:94 Page 14 of 14
http://www.biomedcentral.com/1471-2202/13/9455. McBurney RN, Neering IR: The measurements of changes in intracellular
free calcium during action potentials in mammalian neurons. J Neurosci
Methods 1985, 13:65–76.
56. Wang LY, Dudek EM, Browning MD, MacDonald JF: Modulation of AMPA/
kainate receptors in cultured murine hippocampal neurons by protein
kinase C. J Physiol 1994, 475:431–437.
57. Coyle JT, Puttfarcken P: Oxidative stress, glutamate, and
neurodegenerative disorders. Science 1993, 262:689–695.
58. Crompton M, Costi A: Kinetic evidence for a heart mitochondrial pore
activated by Ca2+, inorganic phosphate and oxidative stress. A potential
mechanism for mitochondrial dysfunction during cellular Ca2+ overload.
Eur J Biochem 1988, 178:489–501.
59. Duchen MR: Contributions of mitochondria to animal physiology: from
homeostatic sensor to calcium signaling and cell death. J Physiol 1999,
516:1–17.
60. Nicholls DG, Budd SL: Mitochondria and neuronal survival. Physiol Rev
2000, 80:315–360.
61. Packer MA, Murphy MP: Peroxynitrite formed by simultaneous nitric oxide
and superoxide generation causes cyclosporin-A-sensitive mitochondrial
calcium efflux and depolarization. Eur J Biochem 1995, 234:231–239.
62. Auer RN: Insulin, blood glucose levels, and ischemic brain damage.
Neurology 1998, 51S3:S39–S43.
63. Zhu CZ, Auer RN: Optimal blood glucose levels while using insulin to
minimize the size of infarction in focal cerebral ischemia. J Neurosurg
2004, 101:664–668.
64. Hamilton MG, Tranmer BI, Auer RN: Insulin reduction of cerebral infarction
due to transient focal ischemia. J Neurosurg 1995, 82:262–268.
65. Nagamizo D, Tsuruta S, Matsumoto M, Matayoshi H, Yamashita A, Sakabe T:
Tight glycemic control by insulin, started in the preischemic, but not
postischemic, period, protects against ischemic spinal cord injury in
rabbits. Anesth Analg 2007, 105:1397–1403.
66. Huang CW, Cheng JT, Tsai JJ, Wu SN, Huang CC: Diabetes aggravates
epileptic seizures and status epilepticus-induced hippocampal damage.
Neurotox Res 2009, 15:71–81.
67. Stafstrom CE: Hyperglycemia lowers seizure threshold. Epilepsy Curr 2003,
3:148–149.
68. Like AA, Rossini AA: Streptozotocin-induced pancreatic insulitis: new
model of diabetes mellitus. Science 1976, 193:415–417.
69. Meldrum B, Garthwaite J: Excitatory amino acid neurotoxicity and
neurodegenerative disease. Trends Pharmacol Sci 1990, 11:379–387.
70. Lipton SA, Rosenberg PA: Excitatory amino acids as a final common
pathway for neurologic disorders. N Engl J Med 1994, 330:613–622.
71. Weiss JH, Sensi SL, Koh JY: Zn(2+): a novel ionic mediator of neural injury
in brain disease. Trends Pharmacol Sci 2000, 21:395–401.
72. Suh SW, Hamby AM, Swanson RA: Hypoglycemia, brain energetic, and
hypoglycemic neuronal death. Glia 2007, 55:1280–1286.
73. Wieloch T: Hypoglycemia-induced neuronal damage prevented by an
N-methyl-D-aspartate antagonist. Science 1985, 230:681–683.
74. Friberg H, Ferrand-Drake M, Bengtsson F, Halestrap AP, Wieloch T:
Cyclosporin A, but not FK 506, protects mitochondria and neurons
against hypoglycemic damage and implicates the mitochondrial
permeability transition in cell death. J Neurosci 1998, 18:5151–5159.
75. Blattner RJ: Central nervous system damage and hypoglycemia. J Pediatr
1968, 72:904–906.
76. Vannucci RC, Vannucci SJ: Hypoglycemic brain injury. Semin Neonatol 2001,
6:147–155.
77. Cronberg T, Rytter A, Asztély F, Söder A, Wieloch T: Glucose but not lactate
in combination with acidosis aggravates ischemic neuronal death
in vitro. Stroke 2004, 35:753–757.
78. Faraco G, Fossati S, Bianchi ME, Patrone M, Pedrazzi M, Sparatore B,
Moroni F, Chiarugi A: High mobility group box 1 protein is released
by neural cells upon different stresses and worsens ischemic
neurodegeneration in vitro and in vivo. J Neurochem 2007, 103:590–603.
79. Racine RJ: Modification of seizure activity by electrical stimulation. II.
Motor seizure. Electroencephalogr Clin Neurophysiol 1972, 32:281–294.
80. Sperk G: Kainic acid seizures in the rat. Prog Neurobiol 1994, 42:1–32.
81. Sidman RL, Angevine JB, Taber Pierce E: Atlas of the Mouse Brain and Spinal
Cord. Cambridge: Harvard University Press; 1971.
82. Franklin KBJ, Paxinos G: The Mouse Brain in Stereotaxic Coordinates. New
York: Academic; 1997.83. Sousa N, Madeira MD, Paula-Barbosa MM: Effects of corticosterone
treatment and rehabilitation on the hippocampal formation of
neonatal and adult rats. An unbiased stereological study. Brain Res 1998,
794:199–210.
84. West MJ, Slomianka L, Gundersen HJ: Unbiased stereological estimation of
the total number of neurons in the subdivisions of the rat hippocampus
using the optical fractionators. Anat Rec 1991, 231:482–497.
doi:10.1186/1471-2202-13-94
Cite this article as: Schauwecker: The effects of glycemic control on
seizures and seizure-induced excitotoxic cell death. BMC Neuroscience
2012 13:94.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
